SIGUIENTE ... : " IDEAYA BIOSCIENCES HA INICIADO UNA COLABORACIÓN CLÍNICA Con ASTRAZENECA " Para Probar el Conjugado Anticuerpo-Fármaco en Fase de Investigación IDE849 , Dirigido Contra la Proteína DLL3 TOP1 , Junto Con el Inhibidor de PD-L1 DURVALUMAB ( IMFINZI de ASTRAZENECA ) , en PACIENTES con SMALL CELL LUNG CANCER EXTENSIVE-STAGE .... ¿ PORQUE NO ELIGIERON AL ATEZOLIZUMAB ... ?
10 octubre 2012
Lurbinectedin ( PharmaMar ) . New Animal Models can Revolutionize the Study of Cancer .
...
Doxil , J&J Ya ha Pedido a la FDA y a la EMEA una Aprobación para Fabricar de Nuevo el Farmaco .
... Now, J&J wants to enlist Ben Venue's help again. As The Wall Street Journal reports, J&J's new Doxil plan would rely on Ben Venue to produce the drug, in areas of its Bedford plant that are now available and approved for use. Another supplier would handle sterile filtration and aseptic filling, to make sure the drug isn't contaminated.
J&J has asked FDA and its counterparts in the EU to approve the new process, the WSJ says. That would amp up Doxil supplies in the short term, giving J&J time to find a long-term manufacturer for Doxil.
J&J has asked FDA and its counterparts in the EU to approve the new process, the WSJ says. That would amp up Doxil supplies in the short term, giving J&J time to find a long-term manufacturer for Doxil.
Suscribirse a:
Comentarios (Atom)